L718Q/V mutation in exon 18 of EGFR mediates resistance to osimertinib: clinical features and treatment

Meihui Li1,2,3,4 · Jing Qin1,2,3 · Fajun Xie1,2,3 · Lei Gong1,2,3 · Na Han1,2,3 · Hongyang Lu1,2,3

Received: 21 June 2022 / Accepted: 3 August 2022
Published online: 9 August 2022
© The Author(s) 2022  OPEN Published online: 9 August 2022

Abstract
Osimertinib, a mutant-specific third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is emerging as the preferred first-line of treatment for EGFR-mutant lung cancer. However, osimertinib resistance inevitably develops among patients treated with the drug. The modal resistance mechanisms of osimertinib include the occurrence of epithelial transition factor (c-MET) amplification and C797S mutation, whereas rare mutations are presented as case reports. Recently, the L718Q/V mutation in exon 18 of EGFR has been reported to contribute to one of the possible mechanisms of resistance. The clinical features and subsequent treatment strategies for this mutation require further research. This study retrospectively enrolled NSCLC patients with the L718Q/V mutation from 2017 to 2021 at the Cancer Hospital of the University of the Chinese Academy of Sciences (Zhejiang Cancer Hospital), as well as additional patients with the same mutation from PubMed literature, to summarize the clinical features of the mutation. The association between the detection of L718Q/V and resistance to osimertinib, as well as impacts on the therapeutic process and outcome, was analyzed. We included a total of two patients diagnosed at Zhejiang Cancer Hospital and twelve patients from the literature. Of the fourteen total patients, 64.3% were male and 35.7% were female. The average age of the group was 60.2 years (range 45–72). A history of tobacco use was common among the group. In all of the cases we considered, the L718Q/V mutation was secondary to the L858R mutation. The second-generation TKI afatinib was found to provide a high disease control rate (DCR) (85.7%, 6/7) and relatively low objective response rate (ORR) (42/9%, 3/7). The median progression free survival (mPFS) for this treatment reached 2 months (1–6 months). The patients failed to benefit from chemotherapy combined with immunotherapy or other TKI medications. Due to the limited number of cases considered in this study, future studies should explore drugs that more precisely target the L718Q/V mutation of EGFR exon 18.

Keywords  L718Q/V mutation of EGFR exon 18 · EGFR T790M mutation · Osimertinib · Resistance mechanism · Afatinib

1 Introduction

The strategy for treating non-small cell lung cancer (NSCLC) has drastically changed over the past few decades, shifting from traditional therapy including surgery, radiotherapy, and chemotherapy to newer classes of treatment such as target-therapy and immunotherapy. Many large-scale clinical trials have demonstrated that targeted drugs, such as
Brief communication Discover Oncology (2022) 13:72 | https://doi.org/10.1007/s12672-022-00537-7

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), have become a major and preferred treatment modality for advanced NSCLC with EGFR mutations. Among these medications, the third-generation targeted drug osimertinib has resulted in significant improvements in progression free survival (PFS) and overall survival (OS), both in the second-line treatment of patients with acquired T790M mutations [1, 2] and the first-line treatment of locally advanced or metastatic EGFR-mutant NSCLC [3, 4]. Nevertheless, the development of osimertinib resistance among these patients has been a gradual and inevitable trend, limiting the median PFS to 10.1 months [1, 5, 6]. The mechanisms of osimertinib resistance can be roughly divided into the following two classes: the EGFR-related drug resistance mechanism, and the EGFR-unrelated drug resistance mechanism, and so on [7]. The stage of cancer and type of genetic mutation have been found to be associated with drug resistance, as especially evident in the mechanism of osimertinib resistance. It is prospective to explore the drug resistance mechanism after the application of osimertinib and find out the effective drugs.

In this paper, we retrospectively analyzed two cases of lung adenocarcinoma with L718Q/V mutations of EGFR exon 18 through next generation sequencing (NGS) technique. The L718 residue of the EGFR exon 18 is located at the ATP binding site of the EGFR kinase domain inducing the L718Q and L718V mutations [7]. After reviewing the therapeutic history for both patients, we speculated that the presence of the L718Q/V mutation in EGFR exon 18 may contribute to the acquired resistance mechanism of the EGFR T790M mutation. Furthermore, we integrated previous reports on treatments involving the L718Q/V mutation into our discussion to explore the most effective therapeutic strategies that may be used after the occurrence of this mutation.

2 Materials and methods

2.1 Patient and clinical sample collection

A comprehensive search was performed through PubMed using the literature retrieval strategy “[EGFR L718Q] OR [EGFR L718V] AND [Osimertinib (Title/Abstract)]” in December 2021 (no year limit and all languages included). Relevant articles were obtained, and references from each of these articles were further searched for relevant articles. A total of 14 articles were reviewed (case reports or case series) and 12 patients with definite molecular pathological diagnosis were collected. Two patients confirming EGFR L718Q/V in Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital) were enrolled with a history of EGFR-TKIs application based on patient’s genetic testing results.

2.2 DNA extraction and NGS

DNA was extracted from tumor tissue, plasma, and cerebrospinal fluid. Library preparation and quantification were carried out. Then, we performed hybridization based on targeted enrichment and sequencing. Briefly, circulating tumor DNA (ctDNA) was extracted using the ATG-Seq technique (liquid biopsy system) by following an optimized version of the manufacturer’s protocols. The ctDNA was examined for 139 lung cancer-related genes based on the LungTrak panel, which includes diverse Chinese data and the well-regarded TCGA database. The results of this analysis included mutations related to lung cancer (point mutations and small fragment insertion-deletion mutations), gene fusion and copy number variations, microsatellite (MS) analysis, and tumor mutant load (TMB).

2.3 Curative effect judgment

Patient’s response to therapies and the progression of different metastatic lung lesions were monitored by computed tomography (CT) imaging and clinical symptoms plus laboratory inspections. The response evaluation was assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1) including complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD) [8]. The OS and PFS were used as the observation indexes.
2.4 Follow-up

The follow-up deadline was December 31, 2021. Two patients were deceased. The survival time was counted from the date of pathological diagnosis.

3 Results

3.1 Overview of the patients

Of the fourteen total patients with L718Q/V mutations in exon 18 of EGFR that were enrolled in our study, two were diagnosed at our hospital and twelve were from PubMed literature. The basic clinical features of the patients are classified in Table 1. Nine (64.3%) of the patients were male and five (35.7%) were female. The study group was composed of middle aged and elderly individuals, with an average age of 60.2 years and age range of 45–72 years. Nine of the patients (64.3%) were smokers. At the time of diagnosis, six of the patients (42.9%) had stage IV cancer, one (7.1%) had stage IIB cancer, and the stage of the remaining seven patients (50%) was unknown.

3.2 NGS

The L718V mutation was not originally detected in liquid or tissue biopsies taken at the time of diagnosis for any of the patients prior to starting osimertinib therapy. Additionally, the original mutation present in all patients was L858R in EGFR exon 21. None of the patients developed alterations in EGFR C797S resistance or any other molecular mechanisms of resistance, at the time of progression on osimertinib.

3.3 Treatment process of the two cases

Two cases involving L718Q mutations were followed as part of this study. Flow charts for the diagnosis and treatment of these patients are shown in Figs. 1 and 2. The first case describes a 62-year-old male patient who complained of shortness of breath in March of 2017. This patient was diagnosed with lung adenocarcinoma and bone metastasis (cT2N1M1, stage IV, L858R mutation in EGFR exon 21) and was treated accordingly with icotinib. A pulmonary biopsy revealed a T790M mutation in EGFR, which led to the initiation of treatment with osimertinib. The patient was classified with progressive disease (PD) status, and the combination of immunotherapy and chemotherapy was applied for one cycle. Subsequently, the L718V and L718Q mutations in exon 18 of EGFR were found from NGS of the cerebrospinal fluid (CSF). Afatinib was added to the current medications for three cycles,
and the best curative effect achieved stable disease (SD) status. Later, afatinib was replaced with osimertinib for four months due to PD status. The addition of pemetrexed on the basis of immunotherapy and targeted therapy resulted in seven months of PFS. The patient died of PD on December 18, 2020.

The second case follows a patient diagnosed with lung adenocarcinoma with multiple metastases (cT2N0M1, stage IV, L858R mutation in exon 21 of EGFR) in February of 2018. Gefitinib and radiotherapy were applied as treatment, resulting in rapid and long-term improvement. After the T790M mutation in exon 20 of EGFR was discovered, treatment with osimertinib was initiated. The combination of chemotherapy and radiotherapy was employed for six cycles due to PD status. Later, a plasma biopsy revealed the appearance of the L718V mutation in EGFR, and anlotinib was subsequently added into the treatment scheme. However, the patient died less than 1 month later.

### 3.4 Patient outcomes and survival

The two patients at our center had died by the time of the follow-up deadline. With the application of EGFR-TKIs against the L858R mutation, the patients gained 5–27 months of PFS (mean: 13.3 months; median: 12 months). Of
the fourteen total patients, seven received afatinib, three received dacomitinib, two received erlotinib, one received anlotinib, and one received best supportive care (BSC) due to poor performance status (PS) as the follow-up treatment. The incidence of the L718Q/V mutation resulted in an average of 2.6 months of PFS (range 1–6 months). Three (21.4%) achieved partial remission (PR), four (28.6%) achieved SD, and six (42.9%) achieved PD. The objective remission rate (ORR) for this group was 21.4% (3/14). Of the seven patients who received afatinib, two were simultaneously undergoing other therapies such as radiotherapy, chemotherapy, and immunotherapy. The disease control rate (DCR) for the afatinib treatment group was 85.7% (6/7), and the ORR 42.9% (3/7). Of the three patients who received dacomitinib as subsequent therapy, PFS of each patient was 1 month. Overall survival (OS) ranged from 23 to 46 months. After the emergence of the L718Q/V mutation, OS ranged from 1 to 14 months. The treatments and prognoses of the patients are summarized in Fig. 3.

4 Discussion

According to previous researches, the median PFS of osimertinib for the T790M mutation is 10.1 months [1, 5, 6], and majority of patients develop resistance to the drug within one year of therapy onset [9, 10]. Exploring the mechanism of osimertinib resistance may prolong its period of effective action, and therefore bring benefits to patients.
In recent years, the potential mechanisms of resistance to osimertinib have been explored. Research has shown that osimertinib resistance may involve acquired mutations in EGFR-independent c-MET amplification [7] and EGFR-dependent C797S [11], or rare mutations at positions P596L [1], L792 [12], G796 [13], and G724S [14]. In this study, we followed two patients with EGFR T790M mutations. These patients were treated with osimertinib, and acquired resistance less than half a year after initiating treatment. These patients also developed L718Q/V mutations in exon 18 of EGFR. Therefore, we speculate that the L718Q/V mutation in exon 18 of EGFR contributes to one of the mechanisms of acquired resistance to osimertinib. Previous studies have revealed that the L718Q mutation in EGFR, with or without the T790M mutation, accounts for approximately 2% of all patients with osimertinib resistance [5, 6, 15]. The L718 residue is located at the ATP binding site of the EGFR kinase domain, where mutations may lead to spatial structural variation and further block the binding of osimertinib to EGFR [7]. The relationship between L718Q/V and osimertinib has been studied in some previous reports. Zhu SJ [16] proved that L718V is a missense mutation that occurs in an ATP binding hydrophobic clamp region. It is hypothesized that mutations of the hydrophobic clamp may affect the binding affinity of any inhibitor that interacts with it. Yang Z et al. [15] found that the L718Q mutation in EGFR conferred the highest resistance to osimertinib by affecting the conformation of the EGFR-osimertinib complex. Liu et al. [17] demonstrated that in vitro cells expressing EGFR L858R/L718V were able to grow better compared to those expressing L858R, it means L718V is oncogenic and renders growth advantage. The researchers also employed in silico protein structure modeling and found that L718V likely introduces a spatial confliction that prevents osimertinib from binding to EGFR.

According to the 14 patients we examined, the L718Q/V mutation was more likely to occur in middle to elderly aged male NSCLC patients with a history of tobacco use. Furthermore, this mutation did not seem specific to any pulmonary lesion location. Until now, patients with the L718V/Q mutation did not have specific and effective treatment guidelines and had to try different experimental medications. A study of transgenic murine models found that the L718Q/V mutation occurs almost exclusively in the setting of an L858R driver mutation, which was consistent with the cases examined in this paper [18]. Furthermore, in vivo models were found to show sensitivity to afatinib while demonstrating resistance to...
gefitinib, erlotinib, and osimertinib. Ercan [19] proved that in the presence of an EGFR-activating mutation alone, afatinib and a novel TKI in development (CL-387785) were particularly effective at inhibiting the growth of both L718Q- and L844V-mutant cells, and consequently inhibited EGFR phosphorylation and activity. The above diverse drug susceptibilities were also applied to the L718V mutation of EGFR exon 18, but the accuracy of this conclusion needs to be verified due to the rare occurrence rate of the mutation. After the occurrence of L718Q/V, the PFS for the 14 patients included in this study ranged from 1 to 6 months, and the OS ranged from 1 to 14 months. In a retrospective study which applied afatinib to non-classical EGFR mutations, the ORR was 65.2% (n = 75) [20]. The ORR was 42.9% (3/7) with a high DCR in the patients treated with afatinib that we studied, the rapid progression may be attributed to the fact that the patients were all treated in the posterior line or the cachexia. In the future, more intensive clinical experimental studies are needed to prove the efficacy of afatinib on account of the rarity of cases. Other second-generation EGFR-TKI Dacomitinib may be ineffective in patients with L718Q/V mutation providing PFS of only 1 months in three patient [21]. In addition, there is currently no relevant research that explores whether the occurrence of L718Q/V will affect the prognosis of the patient – in other words, future research should investigate whether the mutation is a marker of poor prognosis.

5 Conclusion

The L718Q/V mutation in exon 18 of EGFR may contribute to the mechanism of osimertinib resistance. Until now, there has been no recommended treatment guidance for this mutation. Future clinical studies should apply different medications in more intensive experimental studies to better understand the optimal treatment strategy. Although clinical trials on the various mechanisms of drug resistance have been conducted, some clinical applications are still far from effective. Therefore, the primary future research directions of oncological medicine should focus on exploring potential drug resistance mechanisms and more reasonable strategies of drug timing.

Acknowledgements This study was supported by the Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital).

Author contributions ML wrote the main manuscript text. ML and HL prepared Figs. 1–3. JQ, FX, LG, NH and HL were responsible for supervision and critical revisions for important intellectual content. All authors read and approved the final manuscript.

Funding This work was not been supported by fundings.

Data availability The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate The protocol was approved by Medical Ethics Committee of Zhejiang Cancer Hospital. The patients/participants provided their written informed consent to participate in this study. As the patient specimens were collected in a retrospective approach, and the patients were deceased, exempt written informed consents were also approved by the Medical Ethics Committee of Zhejiang Cancer.

Competing interests The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Mok TS, Wu Y-L, Ahn M-J, et al. Osimertinib or Platinum-Pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017;376(7):629–40.
2. Papadimitrakopoulou VA, Mok TS, Han JY, et al. Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis. Ann Oncol. 2020;31(11):1536–44.
3. Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378(2):113–25.
4. Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with Osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382(1):41–50.
5. Le X, Puri S, Negrao MV, et al. Landscape of EGFR-dependent and -independent resistance mechanisms to osimertinib and continuation therapy beyond progression in EGFR-mutant NSCLC. Clin Cancer Res. 2018;24(24):6195–203.
6. Oxnard GR, Hu Y, Mileham KF, et al. Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib. JAMA Oncol. 2018;4(11):1527–34.
7. Liu YY, Wang JG. Research progress of resistance mechanisms and therapeutic strategies of the third generation EGFR-TKIs in non-small cell lung cancer with EGFR sensitive mutation. J Cancer Control Treat. 2020;33(9):792–8.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.